A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity

Trial Profile

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Chronic myelomonocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Mar 2018 Planned End Date changed from 1 Jul 2019 to 1 Apr 2020.
    • 28 Mar 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Apr 2019.
    • 12 Dec 2017 Combine results of phase I and II presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top